Willow GLP-1 Microbiome+ Review: Formula, Cost and Evidence

Willow GLP-1 Microbiome+ is a probiotic–prebiotic supplement, not a treatment for medication side effects. Its clearest selling point is an identifiable formula. Its main limitation is the distance between research on ingredients and proof that this particular combination helps someone taking a GLP-1.

What is in Microbiome+?

The listed daily serving contains 2.5 billion CFU of Lactobacillus plantarum OM (ATCC 55981) and 1,000 mg of PreticX xylooligosaccharide, or XOS. Directions call for two capsules daily ¹. Those details make it possible to ask useful questions about the strain, dose and intended outcome rather than buying on the word “microbiome.”

The supplement is separate from Willow's prescription service. Our GLP-1 program comparison covers clinical services. Buying capsules does not establish eligibility for medication, and a prescription does not establish that an additional supplement is necessary. Our guide to probiotics alongside GLP-1 treatment explains the distinction.

Price and subscription terms

The advertised three-month supply costs $59 once or $50.15 on a quarterly subscription, with free shipping and a pause/cancel option ¹. Dividing those totals across three months gives approximately $19.67 or $16.72 per month. The full quarterly amount, rather than that monthly equivalent, is the purchasing commitment.

Willow bills two days before shipment and recommends canceling at least two days before billing. Processed renewals are final sale for change-of-mind purchases ⁵.

Compare a recurring purchase with a one-time experiment before selecting a plan. A discounted delivery is only useful if you still want the product when it renews. The cost-per-day guide shows how to compare serving quantities and commitment lengths without mistaking a bottle price for value.

What the XOS trials actually show

A 2014 randomized, placebo-controlled trial enrolled 32 healthy adults and tested 1.4 or 2.8 grams of XOS daily for eight weeks. Both groups had increased Bifidobacterium counts compared with placebo, with a greater increase at the higher dose. Lactobacillus counts did not differ significantly, and there were no significant effects on stool pH, short-chain fatty acids or lactic acid ².

That is an interesting microbiology result. It does not establish relief of constipation, nausea or sulfur burps during prescription treatment. The trial evaluated XOS, rather than the Willow combination, at doses above the amount listed in this supplement. More is not automatically better, but a different dose means the result cannot simply be transferred to a bottle with the same ingredient name.

Microbiome changes are not the same as metabolic benefits

A second pilot randomized 13 adults with prediabetes and 16 healthy adults to 2 grams of XOS daily or placebo for eight weeks. The researchers reported changes in bacterial taxa. In the prediabetes group, they found no effect on body composition, HOMA-IR, serum glucose, triglycerides, satiety hormones or TNF-alpha. A tendency toward lower two-hour insulin was not statistically significant ³.

The distinction matters when a product sits beside weight-management treatment. A change in a stool sample should not be described as proof of weight loss, improved blood sugar or increased GLP-1 activity. Neither of these trials establishes that buying this finished supplement will make a prescribed medicine easier to tolerate. They are reasons to investigate a hypothesis, rather than clinical promises for the purchaser.

Does the probiotic strain change the answer?

NIH's probiotic fact sheet explains why genus and species names are insufficient: findings are often specific to the strain and the condition studied. A larger CFU count alone does not establish greater benefit ⁴. A successful trial of another Lactobacillus plantarum strain therefore cannot stand in for a trial of OM in people using a particular medicine.

The practical question is specific: what outcome was measured with this strain, at this dose, in people with the problem you are trying to address? General statements about gut balance do not answer it. Our strain finder and strain evidence lookup help explain why matching the name matters.

Who might consider it, and who should look elsewhere?

It may interest someone who specifically wants to try a named probiotic–XOS combination, understands the uncertainty and is comfortable with the purchase terms. The formula is easier to evaluate than an unnamed blend whose individual ingredients cannot be compared with published research. That is a transparency advantage, not an effectiveness score.

It is a weaker purchase for someone expecting reliable relief from a medication problem or a proven weight-loss effect. A dietary supplement should not delay a conversation with the prescribing clinician about persistent symptoms. NIH also notes that probiotics can cause adverse effects and that people with severe illness or compromised immune systems warrant particular caution ⁴.

If your goal is regularity, begin by defining the problem and comparing relevant evidence, rather than stacking products. Read the GLP-1 constipation guide, fiber and GLP-1 overview, and psyllium-versus-inulin comparison. These options are not interchangeable, and adding several at once makes it harder to tell what is helping or causing discomfort.

Our verdict

Microbiome+ offers a clearly named combination at a price that can be compared by serving and billing cycle. We would choose it only as an optional supplement with limited expectations. Ingredient trials provide context, but the evidence reviewed here does not establish this product as a solution for GLP-1 side effects. The most useful next step is to compare the exact formula with the outcome you want, not assume that “made for GLP-1” closes that evidence gap.